Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 123Unknown 42Terminated 23Active not recruiting 8Withdrawn 3Suspended 1Recruiting 1

Sponsor Class

OTHER 49INDUSTRY 22NIH 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Neoplasms 14Multiple Myeloma 11Lymphoma 11Breast Neoplasms 10Melanoma 7Neoplasm Metastasis 6Colorectal Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Lung Neoplasms 5Leukemia 5Colonic Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroblastoma 3Neoplasms, Plasma Cell 3Mesothelioma, Malignant 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3

Interventions

obatoclax 1gusacitinib 1Rituximab 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Immunization, Passive 1Bendamustine Hydrochloride 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × NIH × Lymphoma, Follicular × Clear all
NCT06238531 2025-03-13

A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Lymphoid

Lupus Erythematosus, Systemic, Lymphoma, Follicular

NCT00024115 2015-04-28

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01238146 2013-06-06

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡